Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALY-002 IV multiple-dose study in celiac disease and eosinophilic esophagitis
NL-OMON52682Completed
- Sponsor
- Calypso Biotech
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of caly-002 in celiac disease and eosinophilic esophagitis (EoE) (5 cohorts), sponsored by Calypso Biotech. Started Oct 2021; status: completed.
02
Drugs
caly-002
03
Conditions
celiac diseaseeosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON52682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52682.